Sequential phase II trials of fluorouracil and interferon β(ser) with or without sargramostim in patients with advanced colorectal carcinoma

Scott Wadler, Hilda Haynes-Lewis, Alla Rozenblit, Xiaoping Hu, Ron Kaleya, Peter H. Wiernik

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta(ser) (IFN β(ser)) may augment the anticancer activity of 5-fluorouracil (5-FU). The current studies were undertaken to explore the optimal schedule of IFN β(ser) and to determine whether the hematopoietic growth factor sargramostim (granulocyte-macrophage colony- stimulating factor) could reduce the hematologic and gastrointestinal toxicities of the chemotherapy. METHODS: Three sequential, single- institution phase II trials using different regimens were initiated. Patients were required to have advanced, histologically documented colorectal carcinoma with no prior chemotherapy; to have adequate bone marrow, renal, and hepatic function; to be fully ambulatory; and to give informed consent. All patients received 5-FU, 750 mg/m2 intravenously as an infusion daily for 5 days, followed by 5-FU, 750 mg/m2, as an intravenous bolus every week beginning day 15. Patients in arm A received IFN β(ser), 9 MU subcutaneously, three times a week. Patients in arm B received IFN β(ser), 9 MU subcutaneously every day. Patients in arm C were treated exactly as in arm B but also received sargramostim, 250 μg subcutaneously on days they did not receive 5-FU. Beginning day 15, all patients received IFN β(ser) exactly 10 minutes before receiving the 5-FU bolus. RESULTS: There were 81 patients enrolled: 19 in arm A; 40 in arm B; and 22 in arm C. Myelosuppression and diarrhea were the most common toxicities. Increasing the frequency of IFN β(ser) administration in arm B resulted in a doubling of the rate of diarrhea from 11% to 22%, and the addition of sargramostim in arm C failed to reduce this. Sargramostim did reduce the incidence of grade 3 to 4 leukopenia, but this did not allow intensification of dosing or result in improved response or survival among patients in ann C, IFN-mediated fatigue was also common, occurring in 37% to 43% of patients. Patients receiving IFN β(ser) on the intermittent schedule tolerated full-dose therapy longer than those on the daily schedule (10 weeks versus 5 weeks, P < 0.01). The response rates in the three arms were 21%, 35%, and 27%; there was no difference in median survival (15 months for all three arms). CONCLUSIONS: The combination of 5-FU and IFN β(ser) was active in patients with advanced colorectal carcinoma, and survival with this regimen was comparable to or better than that with other modulating regimens. The intermittent schedule of IFN β(ser) was better tolerated than the daily schedule.

Original languageEnglish (US)
Pages (from-to)331-337
Number of pages7
JournalCancer Journal from Scientific American
Volume4
Issue number5
StatePublished - 1998

Fingerprint

Fluorouracil
Interferon-beta
Interferons
Colorectal Neoplasms
Appointments and Schedules
Survival
Diarrhea
sargramostim
Drug Therapy
Leukopenia
Biological Factors
Granulocyte-Macrophage Colony-Stimulating Factor
Informed Consent
Fatigue
Intercellular Signaling Peptides and Proteins
Bone Marrow
Clinical Trials
Kidney
Liver
Incidence

Keywords

  • Biochemical modulation
  • Clinical trial
  • Colon cancer
  • Fluoropyrimidines
  • Interferon beta

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sequential phase II trials of fluorouracil and interferon β(ser) with or without sargramostim in patients with advanced colorectal carcinoma. / Wadler, Scott; Haynes-Lewis, Hilda; Rozenblit, Alla; Hu, Xiaoping; Kaleya, Ron; Wiernik, Peter H.

In: Cancer Journal from Scientific American, Vol. 4, No. 5, 1998, p. 331-337.

Research output: Contribution to journalArticle

@article{2d9cbcbe2eb942b3ae6c1186e3d6c8ee,
title = "Sequential phase II trials of fluorouracil and interferon β(ser) with or without sargramostim in patients with advanced colorectal carcinoma",
abstract = "BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta(ser) (IFN β(ser)) may augment the anticancer activity of 5-fluorouracil (5-FU). The current studies were undertaken to explore the optimal schedule of IFN β(ser) and to determine whether the hematopoietic growth factor sargramostim (granulocyte-macrophage colony- stimulating factor) could reduce the hematologic and gastrointestinal toxicities of the chemotherapy. METHODS: Three sequential, single- institution phase II trials using different regimens were initiated. Patients were required to have advanced, histologically documented colorectal carcinoma with no prior chemotherapy; to have adequate bone marrow, renal, and hepatic function; to be fully ambulatory; and to give informed consent. All patients received 5-FU, 750 mg/m2 intravenously as an infusion daily for 5 days, followed by 5-FU, 750 mg/m2, as an intravenous bolus every week beginning day 15. Patients in arm A received IFN β(ser), 9 MU subcutaneously, three times a week. Patients in arm B received IFN β(ser), 9 MU subcutaneously every day. Patients in arm C were treated exactly as in arm B but also received sargramostim, 250 μg subcutaneously on days they did not receive 5-FU. Beginning day 15, all patients received IFN β(ser) exactly 10 minutes before receiving the 5-FU bolus. RESULTS: There were 81 patients enrolled: 19 in arm A; 40 in arm B; and 22 in arm C. Myelosuppression and diarrhea were the most common toxicities. Increasing the frequency of IFN β(ser) administration in arm B resulted in a doubling of the rate of diarrhea from 11{\%} to 22{\%}, and the addition of sargramostim in arm C failed to reduce this. Sargramostim did reduce the incidence of grade 3 to 4 leukopenia, but this did not allow intensification of dosing or result in improved response or survival among patients in ann C, IFN-mediated fatigue was also common, occurring in 37{\%} to 43{\%} of patients. Patients receiving IFN β(ser) on the intermittent schedule tolerated full-dose therapy longer than those on the daily schedule (10 weeks versus 5 weeks, P < 0.01). The response rates in the three arms were 21{\%}, 35{\%}, and 27{\%}; there was no difference in median survival (15 months for all three arms). CONCLUSIONS: The combination of 5-FU and IFN β(ser) was active in patients with advanced colorectal carcinoma, and survival with this regimen was comparable to or better than that with other modulating regimens. The intermittent schedule of IFN β(ser) was better tolerated than the daily schedule.",
keywords = "Biochemical modulation, Clinical trial, Colon cancer, Fluoropyrimidines, Interferon beta",
author = "Scott Wadler and Hilda Haynes-Lewis and Alla Rozenblit and Xiaoping Hu and Ron Kaleya and Wiernik, {Peter H.}",
year = "1998",
language = "English (US)",
volume = "4",
pages = "331--337",
journal = "Cancer Journal from Scientific American",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Sequential phase II trials of fluorouracil and interferon β(ser) with or without sargramostim in patients with advanced colorectal carcinoma

AU - Wadler, Scott

AU - Haynes-Lewis, Hilda

AU - Rozenblit, Alla

AU - Hu, Xiaoping

AU - Kaleya, Ron

AU - Wiernik, Peter H.

PY - 1998

Y1 - 1998

N2 - BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta(ser) (IFN β(ser)) may augment the anticancer activity of 5-fluorouracil (5-FU). The current studies were undertaken to explore the optimal schedule of IFN β(ser) and to determine whether the hematopoietic growth factor sargramostim (granulocyte-macrophage colony- stimulating factor) could reduce the hematologic and gastrointestinal toxicities of the chemotherapy. METHODS: Three sequential, single- institution phase II trials using different regimens were initiated. Patients were required to have advanced, histologically documented colorectal carcinoma with no prior chemotherapy; to have adequate bone marrow, renal, and hepatic function; to be fully ambulatory; and to give informed consent. All patients received 5-FU, 750 mg/m2 intravenously as an infusion daily for 5 days, followed by 5-FU, 750 mg/m2, as an intravenous bolus every week beginning day 15. Patients in arm A received IFN β(ser), 9 MU subcutaneously, three times a week. Patients in arm B received IFN β(ser), 9 MU subcutaneously every day. Patients in arm C were treated exactly as in arm B but also received sargramostim, 250 μg subcutaneously on days they did not receive 5-FU. Beginning day 15, all patients received IFN β(ser) exactly 10 minutes before receiving the 5-FU bolus. RESULTS: There were 81 patients enrolled: 19 in arm A; 40 in arm B; and 22 in arm C. Myelosuppression and diarrhea were the most common toxicities. Increasing the frequency of IFN β(ser) administration in arm B resulted in a doubling of the rate of diarrhea from 11% to 22%, and the addition of sargramostim in arm C failed to reduce this. Sargramostim did reduce the incidence of grade 3 to 4 leukopenia, but this did not allow intensification of dosing or result in improved response or survival among patients in ann C, IFN-mediated fatigue was also common, occurring in 37% to 43% of patients. Patients receiving IFN β(ser) on the intermittent schedule tolerated full-dose therapy longer than those on the daily schedule (10 weeks versus 5 weeks, P < 0.01). The response rates in the three arms were 21%, 35%, and 27%; there was no difference in median survival (15 months for all three arms). CONCLUSIONS: The combination of 5-FU and IFN β(ser) was active in patients with advanced colorectal carcinoma, and survival with this regimen was comparable to or better than that with other modulating regimens. The intermittent schedule of IFN β(ser) was better tolerated than the daily schedule.

AB - BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta(ser) (IFN β(ser)) may augment the anticancer activity of 5-fluorouracil (5-FU). The current studies were undertaken to explore the optimal schedule of IFN β(ser) and to determine whether the hematopoietic growth factor sargramostim (granulocyte-macrophage colony- stimulating factor) could reduce the hematologic and gastrointestinal toxicities of the chemotherapy. METHODS: Three sequential, single- institution phase II trials using different regimens were initiated. Patients were required to have advanced, histologically documented colorectal carcinoma with no prior chemotherapy; to have adequate bone marrow, renal, and hepatic function; to be fully ambulatory; and to give informed consent. All patients received 5-FU, 750 mg/m2 intravenously as an infusion daily for 5 days, followed by 5-FU, 750 mg/m2, as an intravenous bolus every week beginning day 15. Patients in arm A received IFN β(ser), 9 MU subcutaneously, three times a week. Patients in arm B received IFN β(ser), 9 MU subcutaneously every day. Patients in arm C were treated exactly as in arm B but also received sargramostim, 250 μg subcutaneously on days they did not receive 5-FU. Beginning day 15, all patients received IFN β(ser) exactly 10 minutes before receiving the 5-FU bolus. RESULTS: There were 81 patients enrolled: 19 in arm A; 40 in arm B; and 22 in arm C. Myelosuppression and diarrhea were the most common toxicities. Increasing the frequency of IFN β(ser) administration in arm B resulted in a doubling of the rate of diarrhea from 11% to 22%, and the addition of sargramostim in arm C failed to reduce this. Sargramostim did reduce the incidence of grade 3 to 4 leukopenia, but this did not allow intensification of dosing or result in improved response or survival among patients in ann C, IFN-mediated fatigue was also common, occurring in 37% to 43% of patients. Patients receiving IFN β(ser) on the intermittent schedule tolerated full-dose therapy longer than those on the daily schedule (10 weeks versus 5 weeks, P < 0.01). The response rates in the three arms were 21%, 35%, and 27%; there was no difference in median survival (15 months for all three arms). CONCLUSIONS: The combination of 5-FU and IFN β(ser) was active in patients with advanced colorectal carcinoma, and survival with this regimen was comparable to or better than that with other modulating regimens. The intermittent schedule of IFN β(ser) was better tolerated than the daily schedule.

KW - Biochemical modulation

KW - Clinical trial

KW - Colon cancer

KW - Fluoropyrimidines

KW - Interferon beta

UR - http://www.scopus.com/inward/record.url?scp=0031658269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031658269&partnerID=8YFLogxK

M3 - Article

C2 - 9815298

AN - SCOPUS:0031658269

VL - 4

SP - 331

EP - 337

JO - Cancer Journal from Scientific American

JF - Cancer Journal from Scientific American

SN - 1528-9117

IS - 5

ER -